The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | EGFR mutations increase recurrence in NSCLC
Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, discusses his recent paper on EGFR mutation increasing the risk of recurrence in early-stage, high-risk non-small cell lung cancer (NSCLC). His research shows that this mutation is associated with increases in all types of recurrence, including central nervous system (CNS) metastasis. These results align with the ongoing ADAURA-2 trial (NCT05120349) where the primary endpoint was disease free survival in the high-risk group. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
